[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity
Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos reported two open-market sales of company common stock executed under a Rule 10b5-1 trading plan. On 09/19/2025 he sold 4,870 shares at a weighted average price of $19.1095 and 2,130 shares at a weighted average price of $20.016, for a total of 7,000 shares sold. The filings state the trades were executed in multiple transactions with sale prices ranging from $18.94 to $20.0469. After these sales the reporting person’s beneficial ownership is reported as 933,188 shares held indirectly through The Lyssikatos Revocable Trust, for which he is trustee. The Form 4 was signed by an attorney-in-fact on 09/23/2025.
Il Chief Scientific Officer di Enliven Therapeutics, Joseph P. Lyssikatos, ha riportato due vendite sul mercato aperto di azioni ordinarie della società effettuate secondo un piano di trading Rule 10b5-1. Il 19/09/2025 ha venduto 4.870 azioni a un prezzo medio ponderato di 19,1095 dollari e 2.130 azioni a un prezzo medio ponderato di 20,016 dollari, per un totale di 7.000 azioni vendute. I documenti indicano che le operazioni sono state eseguite in più transazioni con prezzi di vendita che variano da 18,94 a 20,0469 dollari. Dopo tali vendite la detenzione beneficiaria riportata dal soggetto è di 933.188 azioni detenute indirettamente attraverso il The Lyssikatos Revocable Trust, di cui lui è trustee. Il modulo 4 è stato firmato da un procuratore-in-fatto il 23/09/2025.
El director científico de Enliven Therapeutics, Joseph P. Lyssikatos, reportó dos ventas en el mercado abierto de acciones comunes de la compañía realizadas bajo un plan de trading Rule 10b5-1. El 19/09/2025 vendió 4.870 acciones a un precio medio ponderado de 19,1095 dólares y 2.130 acciones a un precio medio ponderado de 20,016 dólares, para un total de 7.000 acciones vendidas. Los archivos señalan que las operaciones se ejecutaron en múltiples transacciones con precios de venta que oscilaron entre 18,94 y 20,0469 dólares. Tras estas ventas, la titularidad beneficiosa reportada del informante es de 933.188 acciones, mantenidas indirectamente a través de The Lyssikatos Revocable Trust, del cual él es fideicomisario. El Formulario 4 fue firmado por un apoderado el 23/09/2025.
Enliven Therapeutics의 최고 과학책임자 Joseph P. Lyssikatos가 Rule 10b5-1 거래계획에 따라 공개시장 매매를 보고했습니다. 2025년 9월 19일 그는 가중평균가 19.1095달러로 4,870주를, 가중평균가 20.016달러로 2,130주를 매도하여 총 7,000주를 매도했습니다. 제출 문서에 따르면 거래는 여러 건의 거래로 실행되었으며 매각 가격은 18.94달러에서 20.0469달러까지였습니다. 이 매도들 이후 보고자의 유익한 소유량은 Lyssikatos Revocable Trust를 통해 간접적으로 보유한 933,188주로 보고되며, 신탁의 수탁자이기도 합니다. Form 4는 2025년 9월 23일 대리인에 의해 서명되었습니다.
Le directeur scientifique d'Enliven Therapeutics, Joseph P. Lyssikatos, a signalé deux ventes sur le marché libre d’actions ordinaires réalisées dans le cadre d’un plan de trading Rule 10b5-1. Le 19/09/2025, il a vendu 4 870 actions à un cours moyen pondéré de 19,1095 dollars et 2 130 actions à un cours moyen pondéré de 20,016 dollars, soit un total de 7 000 actions vendues. Les dépôts indiquent que les transactions ont été exécutées en plusieurs opérations avec des prix de vente allant de 18,94 à 20,0469 dollars. Après ces ventes, la détention bénéficiaire du déclarant est indiquée comme 933 188 actions détenues indirectement par le The Lyssikatos Revocable Trust, dont il est fiduciaire. Le Formulaire 4 a été signé par un mandataire le 23/09/2025.
Der Chief Scientific Officer von Enliven Therapeutics, Joseph P. Lyssikatos, hat zwei Open-Market-Verkäufe von Stammaktien des Unternehmens gemeldet, die im Rahmen eines Rule 10b5-1-Handelsplans erfolgt sind. Am 19.09.2025 verkaufte er 4.870 Aktien zu einem gewichteten Durchschnittspreis von 19,1095 USD und 2.130 Aktien zu 20,016 USD, insgesamt 7.000 Aktien. Die Einreichungen geben an, dass die Geschäfte in mehreren Transaktionen ausgeführt wurden und die Verkaufspreise zwischen 18,94 USD und 20,0469 USD lagen. Nach diesen Verkäufen wird die wirtschaftliche Eigentümerschaft der meldenden Person als 933.188 Aktien angegeben, die indirekt über den The Lyssikatos Revocable Trust gehalten werden, dessen Treuhänder er ist. Das Formular 4 wurde am 23.09.2025 von einem Bevollmächtigten unterzeichnet.
أبلغ المدير العلمي لشركة Enliven Therapeutics، جوزيف ب. ليسيكاطوس، عن بيعين في السوق المفتوح لأسهم الشركة المملوكة عاديًا، التي تمت وفق خطة تداول Rule 10b5-1. في 19/09/2025 باع 4,870 سهماً بسعر متوسط مرجح قدره 19.1095 دولار و2,130 سهماً بسعر متوسط مرجح قدره 20.016 دولار، ليصل الإجمالي إلى 7,000 سهم مباعة. تشير الملفات إلى أن التداولات تمت في عدة عمليات بأسعار بيع تراوحت بين 18.94 و20.0469 دولار. بعد هذه المبيعات، يُذكر أن الملكية المفيدة للمبلغ المعلن عنها هي 933,188 سهماً مملوكة بشكل غير مباشر عبر The Lyssikatos Revocable Trust، الذي هو أمينه. تم توقيع النموذج 4 من قبل وكيل نيابة في 23/09/2025.
Enliven Therapeutics 的首席科学官 Joseph P. Lyssikatos 报告了两笔在公开市场的普通股出售，依据 Rule 10b5-1 交易计划执行。2025-09-19 他以加权平均价格分别为 19.1095 美元卖出 4,870 股，以及以加权平均价格 20.016 美元卖出 2,130 股，总计出售 7,000 股。提交文件显示交易分成多笔，卖出价格区间为 18.94 至 20.0469 美元。经这些出售后，报告人通过 Lyssikatos 可撤销信托（The Lyssikatos Revocable Trust）间接持有的受益所有权为 933,188 股，他为该信托的受托人。Forms 4 于 2025-09-23 由代理人签署。
- Disclosed under a Rule 10b5-1 plan, indicating the sales were pre-arranged and intended to comply with insider trading rules
- Full Form 4 disclosure includes number of shares, weighted average prices, price ranges, and the indirect ownership vehicle
- Reporting person offers to provide detailed per-trade sale information on request, increasing transparency
- Insider sold 7,000 shares on 09/19/2025, which reduced reported beneficial ownership to 933,188 shares
- Sales executed in multiple trades across price ranges, which may complicate immediate assessment of the precise timing and allocation of proceeds without requesting per-trade details
Insights
TL;DR: Routine disclosure of insider sales under a documented 10b5-1 plan; transparency is maintained.
The Form 4 shows a named officer executed sales pursuant to a Rule 10b5-1 plan adopted on November 15, 2024, which provides an affirmative defense under insider trading rules. The filing discloses the number of shares sold (7,000), the weighted average prices and price ranges, and the indirect ownership vehicle (a revocable trust). This level of disclosure aligns with good governance practices by documenting the plan date and offering to provide per-trade details on request. No derivative transactions or amendments to previously reported holdings are disclosed beyond the reported sales.
TL;DR: Officer sold 7,000 shares in multiple trades; reported holdings remain above 900k shares.
The reported sales consist of 4,870 shares at a weighted average of $19.1095 and 2,130 shares at a weighted average of $20.016 executed on 09/19/2025 under a 10b5-1 plan. The filer reports beneficial ownership of 933,188 shares held indirectly via a revocable trust. The filing includes granular price ranges ($18.94–$19.89 and $19.95–$20.0469) and commits to provide detailed per-trade allocation upon formal request. From a market-data perspective this is an insider liquidity event disclosed in compliance with Section 16 reporting requirements; the filing contains no other operational or financial metrics.
Il Chief Scientific Officer di Enliven Therapeutics, Joseph P. Lyssikatos, ha riportato due vendite sul mercato aperto di azioni ordinarie della società effettuate secondo un piano di trading Rule 10b5-1. Il 19/09/2025 ha venduto 4.870 azioni a un prezzo medio ponderato di 19,1095 dollari e 2.130 azioni a un prezzo medio ponderato di 20,016 dollari, per un totale di 7.000 azioni vendute. I documenti indicano che le operazioni sono state eseguite in più transazioni con prezzi di vendita che variano da 18,94 a 20,0469 dollari. Dopo tali vendite la detenzione beneficiaria riportata dal soggetto è di 933.188 azioni detenute indirettamente attraverso il The Lyssikatos Revocable Trust, di cui lui è trustee. Il modulo 4 è stato firmato da un procuratore-in-fatto il 23/09/2025.
El director científico de Enliven Therapeutics, Joseph P. Lyssikatos, reportó dos ventas en el mercado abierto de acciones comunes de la compañía realizadas bajo un plan de trading Rule 10b5-1. El 19/09/2025 vendió 4.870 acciones a un precio medio ponderado de 19,1095 dólares y 2.130 acciones a un precio medio ponderado de 20,016 dólares, para un total de 7.000 acciones vendidas. Los archivos señalan que las operaciones se ejecutaron en múltiples transacciones con precios de venta que oscilaron entre 18,94 y 20,0469 dólares. Tras estas ventas, la titularidad beneficiosa reportada del informante es de 933.188 acciones, mantenidas indirectamente a través de The Lyssikatos Revocable Trust, del cual él es fideicomisario. El Formulario 4 fue firmado por un apoderado el 23/09/2025.
Enliven Therapeutics의 최고 과학책임자 Joseph P. Lyssikatos가 Rule 10b5-1 거래계획에 따라 공개시장 매매를 보고했습니다. 2025년 9월 19일 그는 가중평균가 19.1095달러로 4,870주를, 가중평균가 20.016달러로 2,130주를 매도하여 총 7,000주를 매도했습니다. 제출 문서에 따르면 거래는 여러 건의 거래로 실행되었으며 매각 가격은 18.94달러에서 20.0469달러까지였습니다. 이 매도들 이후 보고자의 유익한 소유량은 Lyssikatos Revocable Trust를 통해 간접적으로 보유한 933,188주로 보고되며, 신탁의 수탁자이기도 합니다. Form 4는 2025년 9월 23일 대리인에 의해 서명되었습니다.
Le directeur scientifique d'Enliven Therapeutics, Joseph P. Lyssikatos, a signalé deux ventes sur le marché libre d’actions ordinaires réalisées dans le cadre d’un plan de trading Rule 10b5-1. Le 19/09/2025, il a vendu 4 870 actions à un cours moyen pondéré de 19,1095 dollars et 2 130 actions à un cours moyen pondéré de 20,016 dollars, soit un total de 7 000 actions vendues. Les dépôts indiquent que les transactions ont été exécutées en plusieurs opérations avec des prix de vente allant de 18,94 à 20,0469 dollars. Après ces ventes, la détention bénéficiaire du déclarant est indiquée comme 933 188 actions détenues indirectement par le The Lyssikatos Revocable Trust, dont il est fiduciaire. Le Formulaire 4 a été signé par un mandataire le 23/09/2025.
Der Chief Scientific Officer von Enliven Therapeutics, Joseph P. Lyssikatos, hat zwei Open-Market-Verkäufe von Stammaktien des Unternehmens gemeldet, die im Rahmen eines Rule 10b5-1-Handelsplans erfolgt sind. Am 19.09.2025 verkaufte er 4.870 Aktien zu einem gewichteten Durchschnittspreis von 19,1095 USD und 2.130 Aktien zu 20,016 USD, insgesamt 7.000 Aktien. Die Einreichungen geben an, dass die Geschäfte in mehreren Transaktionen ausgeführt wurden und die Verkaufspreise zwischen 18,94 USD und 20,0469 USD lagen. Nach diesen Verkäufen wird die wirtschaftliche Eigentümerschaft der meldenden Person als 933.188 Aktien angegeben, die indirekt über den The Lyssikatos Revocable Trust gehalten werden, dessen Treuhänder er ist. Das Formular 4 wurde am 23.09.2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What transactions did Joseph Lyssikatos report on Form 4 for ELVN?
Were the sales by the ELVN officer part of a prearranged plan?
How many ELVN shares does the reporting person own after the reported sales?
Does the Form 4 provide per-trade sale prices for the reported transactions?
Who signed the Form 4?
